✦ LIBER ✦

Phase II Trial of Doxorubicin/Docetaxel/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58

✍ Scribed by Roy E. Smith; Stewart J. Anderson; Ann Brown; Aaron P. Scholnik; Ajit M. Desai; Carl G. Kardinal; Barry C. Lembersky; Eleftherios P. Mamounas

Book ID: 119934627
Publisher: CIG Media Group, LP.
Year: 2002
Tongue: English
Weight: 118 KB
Volume: 3
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2002.n.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial of a Doxorubicin/Docetaxe

Phase II Trial of a Doxorubicin/Docetaxel Doublet for Locally Advanced and Metastatic Breast Cancer: Results from National Surgical Adjuvant Breast and Bowel Project Trial BP-57

✍ Roy E. Smith; Stewart J. Anderson; Barry C. Lembersky; Ann Brown; Eleftherios P. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 152 KB

Docetaxel and Doxorubicin Compared With

Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

✍ Nabholtz, J.-M. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 150 KB

Concurrent Bevacizumab with a Sequential

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

✍ Priya Rastogi; Marc E. Buyse; Sandra M. Swain; Samuel A. Jacobs; André Robidoux; 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 570 KB

P91 Gemcitabine, epirubicin, and docetax

P91 Gemcitabine, epirubicin, and docetaxel (GED) asneoadjuvant therapy. Updated results from a multicenter phase II trial in locally advanced breast cancer

✍ D. Yardley; P. Whitworth; F. Greco; L. Dunbar; H. Burris; M. White; M. Melodie; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 160 KB

A phase I/II trial of non-pegylated lipo

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

✍ D. Amadori; C. Milandri; G. Comella; S. Saracchini; S. Salvagni; C. Barone; R. B 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 226 KB

0178 Results of clinical endpoints of a

0178 Results of clinical endpoints of a randomized phase II trial with doxorubicin + pemetrexed followed by docetaxel versus doxorubicin + cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer

✍ A. Schneeweiss; A. Ruiz; P. Rovira; A. Bottini; A. Manikhas; J. Wacker; T. Schum 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB